Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

WHOLESALER QUARANTINE AREAS FOR RETURNED, DAMAGED AND OUTDATED

Executive Summary

WHOLESALER QUARANTINE AREAS FOR RETURNED, DAMAGED AND OUTDATED items must allow for physical separation from other stock, FDA reiterated in the final state licensing guidelines published in the Sept. 14 Federal Register. Noting that comments had suggested the feasibility of computer quarantining of returned or damaged items, FDA stayed with a physical quarantine requirement. "The agency does not believe," the notice explains, "that a computer-controlled quarantine system which does not provide for physical separation of the drugs, is appropriate." However, FDA has modified the quarantine requirements to clarify that one area can be used as a quarantine for all substandard goods. The final state licensing guidelines made it to the Federal Register almost two years to the day from the original proposal. The guideline is immediately effective, triggering a two-year deadline for states to implement a version of the licensing plan. The licensing requirements are part of the implementation plan for the Prescription Drug Marketing Act of 1987, the Dingell Drug Diversion Act. Responding to comments from the National Wholesale Druggists Association and Rep. Dingell (D-Mich.), FDA removed a requirement that wholesalers include expiration dates in records of their transactions. Dingell had pointed out to the agency in October 1988 that expiration dates do not commonly appear on commercial invoices. Similarly, FDA agreed that inspection of incoming delivery vehicles, as suggested in the initial proposal, goes too far. The agency, instead, is suggesting that the inspection of incoming goods be limited to a "visual examination of shipping containers." FDA specified that "this inspection should be aimed at detecting damage that would suggest possible contamination of the container's contents." FDA will permit reshelving of returned prescription drugs if the wholesaler performs or contracts out for analysis of the product to detect potential problems with safety, identity, strength, quality and purity. If the conditions of return "cast a doubt" on the product's condition, then the wholesaler must destroy the product or return to the supplier "unless examination, testing or other investigation proves that the drug meets appropriate standards," FDA said. As predicted, the revised guidelines will permit an exemption from licensing for chain drug warehouses involved purely in intracompany sales. The agency noted, however, that a "chain drug warehouse that sells prescription drugs to a franchised store or to establishments outside the corporate umbrella...would be engaging in wholesale distribution" and would have to be licensed by a state.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS018086

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel